GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sichuan Huiyu Pharmaceutical Co 688553.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

11.42

-0.09%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Sichuan Huiyu Pharmaceutical Co

Its shares trade on Shanghai under the ticker 688553.SS. It has been listed since 26 October 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥998.1m and a net loss of CN¥24.2m. At that date it held total assets of CN¥5.02bn and shareholders' equity of CN¥3.76bn.

Sichuan Huiyu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Neijiang, Sichuan. The company went IPO on 2021-10-26. The Company’s products are mainly anti-tumor chemical injections, including pemetrexed disodium for injection, docetaxel injection, zoledronic acid injection, irinotecan hydrochloride injection, doxorubicin hydrochloride injection liquid and azacitidine for injection. The firm's products are mainly used in the clinical treatment of various adaptive diseases. The firm distributes its products both in the domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
26 Oct 2021
Employees
1,669

Leadership

Pay as last reported

  • Mr. Zhao DingChairman of the Board, General Manager, since 2010CN¥1.5m
  • Mr. Lan GaoChief Financial Officer, Director, since 2020CN¥652,300
  • Mr. Chunping ZhangDeputy General Manager, Secretary of the Board
  • Mr. Yongchun RenDeputy General ManagerCN¥655,500
  • Mr. Guochang YangDeputy General ManagerCN¥326,400
  • Ms. Ying WuDirector
  • Mr. Xiao YangDirector
  • Mr. Liang YueDirector
  • Ms. Lin ZhouDirector, since 2015CN¥316,100
  • Ms. Xinxin LiangIndependent DirectorCN¥80,000
  • Mr. Yongqiang LongIndependent DirectorCN¥80,000
  • Mr. Yong TanIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 1,669 full-time employees.
  • Products include anti-tumor chemical injections for clinical treatment.
  • Distributes products domestically and internationally.

Weaknesses

  • No specific weaknesses mentioned in the provided information.
  • No details on financial performance or market share provided.
  • No information on R&D investment or product pipeline.

Opportunities

  • Potential growth in anti-tumor pharmaceutical market.
  • Expansion into overseas markets for product distribution.
  • Increasing demand for clinical treatment solutions.

Threats

  • No specific threats mentioned in the provided information.
  • No details on competition or regulatory challenges provided.
  • No information on market saturation or economic factors.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.